NCT03403621View on ClinicalTrials.gov

Hypertrophic Scar Prevention by Novel Topical Gel Application

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

February 26, 2020

Study Completion Date

February 26, 2020

Conditions
Hypertrophic Scar
Interventions
DRUG

Pentamidine Isethionate

Approximately 1.8 mL single dose delivered as topical formulation containing 2% topical pentamidine in silicone-containing base.

DRUG

Placebo

No active ingredient. Approximately 1.8 mL single dose delivered as topical silicone compounding base only.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT03403621 - Hypertrophic Scar Prevention by Novel Topical Gel Application | Biotech Hunter | Biotech Hunter